Ann Chen Wu1, Kelan Tantisira2, Lingling Li3, Brooke Schuemann4, Scott T Weiss2, Anne L Fuhlbrigge5. 1. Center for Child Health Care Studies, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA; Department of Pediatrics, Children's Hospital, Boston, MA; Harvard Medical School, Department of Medicine, Brigham and Women's Hospital, Boston, MA. Electronic address: ann.wu@childrens.harvard.edu. 2. Harvard Medical School, Department of Medicine, Brigham and Women's Hospital, Boston, MA; Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, MA; Center for Genomic Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA. 3. Center for Child Health Care Studies, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA; Harvard Medical School, Department of Medicine, Brigham and Women's Hospital, Boston, MA. 4. Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, MA. 5. Harvard Medical School, Department of Medicine, Brigham and Women's Hospital, Boston, MA; Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Abstract
BACKGROUND: Asthma therapy is typically prescribed and titrated based on patient or parent self-report of symptoms. No longitudinal studies have assessed the relationship between symptoms and severe asthma exacerbations in children. The goal of our study was (1) to assess the association of asthma symptoms with severe asthma exacerbations and (2) to compare predictors of persistent asthma symptoms and predictors of severe asthma exacerbations. METHODS: The Childhood Asthma Management Program was a multicenter clinical trial of 1,041 children randomized to receivebudesonide, nedocromil, or placebo (as-needed β-agonist). We conducted a post hoc analysis of diary cards that were completed by subjects on a daily basis to categorize subjects as having persistent vs intermittent symptoms. We defined a severe asthma exacerbation as an episode requiring ≥ 3 days use of oral corticosteroids, hospitalization, or ED visit due to asthma based on self-report at study visits every 4 months. RESULTS: While accounting for longitudinal measures, having persistent symptoms from asthma was significantly associated with having severe asthma exacerbations. Predictors of having persistent symptoms compared with intermittent symptoms included not being treated with inhaled corticosteroids, lower FEV(1)/FVC ratio, and a lower natural logarithm of provocative concentration of methacholine producing a 20% decline in FEV(1) (lnPC(20)). Predictors of having one or more severe asthma exacerbations included younger age, history of hospitalization or ED visit in the prior year, ≥ 3 days use of oral corticosteroids in the prior 3 months, lower FEV(1)/FVC ratio, lower lnPC(20), and higher logarithm to the base 10 eosinophil count; treatment with inhaled corticosteroids was predictive of having no severe asthma exacerbations. CONCLUSIONS: Patients with persistent symptoms from asthma were more likely to experience severe asthma exacerbations. Nevertheless, demographic and laboratory predictors of having persistent symptoms are different from predictors of severe asthma exacerbations. Although symptoms and exacerbations are closely related, their predictors are different. The current focus of the National Asthma Education and Prevention Program guidelines on the two separate domains of asthma control, impairment and risk, are supported by our analysis.
RCT Entities:
BACKGROUND:Asthma therapy is typically prescribed and titrated based on patient or parent self-report of symptoms. No longitudinal studies have assessed the relationship between symptoms and severe asthma exacerbations in children. The goal of our study was (1) to assess the association of asthma symptoms with severe asthma exacerbations and (2) to compare predictors of persistent asthma symptoms and predictors of severe asthma exacerbations. METHODS: The Childhood Asthma Management Program was a multicenter clinical trial of 1,041 children randomized to receive budesonide, nedocromil, or placebo (as-needed β-agonist). We conducted a post hoc analysis of diary cards that were completed by subjects on a daily basis to categorize subjects as having persistent vs intermittent symptoms. We defined a severe asthma exacerbation as an episode requiring ≥ 3 days use of oral corticosteroids, hospitalization, or ED visit due to asthma based on self-report at study visits every 4 months. RESULTS: While accounting for longitudinal measures, having persistent symptoms from asthma was significantly associated with having severe asthma exacerbations. Predictors of having persistent symptoms compared with intermittent symptoms included not being treated with inhaled corticosteroids, lower FEV(1)/FVC ratio, and a lower natural logarithm of provocative concentration of methacholine producing a 20% decline in FEV(1) (lnPC(20)). Predictors of having one or more severe asthma exacerbations included younger age, history of hospitalization or ED visit in the prior year, ≥ 3 days use of oral corticosteroids in the prior 3 months, lower FEV(1)/FVC ratio, lower lnPC(20), and higher logarithm to the base 10 eosinophil count; treatment with inhaled corticosteroids was predictive of having no severe asthma exacerbations. CONCLUSIONS:Patients with persistent symptoms from asthma were more likely to experience severe asthma exacerbations. Nevertheless, demographic and laboratory predictors of having persistent symptoms are different from predictors of severe asthma exacerbations. Although symptoms and exacerbations are closely related, their predictors are different. The current focus of the National Asthma Education and Prevention Program guidelines on the two separate domains of asthma control, impairment and risk, are supported by our analysis.
Authors: Michael Schatz; David M Mosen; Mark Kosinski; William M Vollmer; David J Magid; Elizabeth O'Connor; Robert S Zeiger Journal: J Asthma Date: 2007-05 Impact factor: 2.515
Authors: Helen K Reddel; D Robin Taylor; Eric D Bateman; Louis-Philippe Boulet; Homer A Boushey; William W Busse; Thomas B Casale; Pascal Chanez; Paul L Enright; Peter G Gibson; Johan C de Jongste; Huib A M Kerstjens; Stephen C Lazarus; Mark L Levy; Paul M O'Byrne; Martyn R Partridge; Ian D Pavord; Malcolm R Sears; Peter J Sterk; Stuart W Stoloff; Sean D Sullivan; Stanley J Szefler; Mike D Thomas; Sally E Wenzel Journal: Am J Respir Crit Care Med Date: 2009-07-01 Impact factor: 21.405
Authors: Angela J Rogers; Kelan G Tantisira; Anne L Fuhlbrigge; Augusto A Litonjua; Jessica A Lasky-Su; Stanley J Szefler; Robert C Strunk; Robert S Zeiger; Scott T Weiss Journal: Pharmacogenomics Date: 2009-08 Impact factor: 2.533
Authors: Jeanne E Moorman; Rose Anne Rudd; Carol A Johnson; Michael King; Patrick Minor; Cathy Bailey; Marissa R Scalia; Lara J Akinbami Journal: MMWR Surveill Summ Date: 2007-10-19
Authors: Ronina A Covar; Stanley J Szefler; Robert S Zeiger; Christine A Sorkness; Mark Moss; David T Mauger; Susan J Boehmer; Robert C Strunk; Fernando D Martinez; Lynn M Taussig Journal: J Allergy Clin Immunol Date: 2008-10 Impact factor: 10.793
Authors: Niloufar Farzan; Susanne J Vijverberg; Anand K Andiappan; Lambang Arianto; Vojko Berce; Natalia Blanca-López; Hans Bisgaard; Klaus Bønnelykke; Esteban G Burchard; Paloma Campo; Glorisa Canino; Bruce Carleton; Juan C Celedón; Fook Tim Chew; Wen Chin Chiang; Michelle M Cloutier; Denis Daley; Herman T Den Dekker; F Nicole Dijk; Liesbeth Duijts; Carlos Flores; Erick Forno; Daniel B Hawcutt; Natalia Hernandez-Pacheco; Johan C de Jongste; Michael Kabesch; Gerard H Koppelman; Vangelis G Manolopoulos; Erik Melén; Somnath Mukhopadhyay; Sara Nilsson; Colin N Palmer; Maria Pino-Yanes; Munir Pirmohamed; Uros Potočnik; Jan A Raaijmakers; Katja Repnik; Maximilian Schieck; Yang Yie Sio; Rosalind L Smyth; Csaba Szalai; Kelan G Tantisira; Steve Turner; Marc P van der Schee; Katia M Verhamme; Anke H Maitland-van der Zee Journal: Pharmacogenomics Date: 2017-06-22 Impact factor: 2.533
Authors: David B Kantor; Molly C McDonald; Nicole Stenquist; Blake J Schultz; Craig D Smallwood; Kyle A Nelson; Wanda Phipatanakul; Joel N Hirschhorn Journal: Am J Respir Crit Care Med Date: 2016-12-15 Impact factor: 21.405
Authors: Shona Fielding; Marielle Pijnenburg; Johan C de Jongste; Katharine C Pike; Graham Roberts; Helen Petsky; Anne B Chang; Maria Fritsch; Thomas Frischer; Stanley Szefler; Peter Gergen; Francoise Vermeulen; Robin Vael; Steve Turner Journal: Chest Date: 2018-10-22 Impact factor: 9.410